Kyverna Therapeutics financials
$6.80−0.58%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$169.8M | -$142.6M |
| Net income | -$161.3M | -$127.5M |
| Net margin | — | — |
| Diluted EPS | $-3.64 | $-3.33 |
| EBITDA | -$168.0M | -$140.5M |
| Operating cash flow | -$153.7M | -$114.3M |
| Free cash flow | -$153.7M | -$116.5M |
| Diluted shares | 44.3M | 38.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $124.1M | $96.6M |
| Short-term investments | $155.2M | $189.4M |
| Total debt | $25.1M | $921.0K |
| Total assets | $293.8M | $304.6M |
| Total liabilities | $61.5M | $38.1M |
| Shareholders' equity | $232.3M | $266.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology